Lynch Asset Management Inc. Raises Stake in Pfizer Inc. (NYSE:PFE)

Lynch Asset Management Inc. increased its position in Pfizer Inc. (NYSE:PFE) by 1.3% during the 4th quarter, Holdings Channel reports. The firm owned 45,500 shares of the biopharmaceutical company’s stock after acquiring an additional 600 shares during the quarter. Lynch Asset Management Inc.’s holdings in Pfizer were worth $1,207,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer in the fourth quarter valued at about $26,000. Gladius Capital Management LP increased its position in Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares during the period. Quarry LP bought a new stake in shares of Pfizer in the 2nd quarter valued at about $31,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Pfizer during the third quarter valued at approximately $35,000. Finally, Joseph Group Capital Management increased its holdings in Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 771 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Down 1.5 %

Shares of PFE opened at $26.51 on Monday. The firm has a 50-day moving average price of $26.27 and a 200 day moving average price of $27.86. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $150.20 billion, a P/E ratio of 35.82, a P/E/G ratio of 0.66 and a beta of 0.64.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.49%. The ex-dividend date of this dividend is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is 232.44%.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Sanford C. Bernstein started coverage on Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.